Heterologous expression of neisserial proteins
AssigneeNovartis Vaccines and Diagnostics, Inc.
InventorsMaria Beatrice Arico, Maurizio Comanducci, Cesira Galeotti, Vega Masignani, Marizia Monica Guiliani, Mariagrazia Pizza
Life of this patent
Estimating the term…
Abstract
Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae. These approaches typically affect the level of expression, the ease of purification, the cellular localisation, and/or the immunological properties of the expressed protein.
Claims52
A method for the heterologous expression of a protein of the invention, in which (a) at least one domain in the protein is deleted and, optionally, (b) no fusion partner is used.
A method for the heterologous expression of a protein of the invention, in which (a) a portion of the N-terminal domain of the protein is deleted.
A method for the heterologous expression of a protein of the invention, in which (a) no fusion partner is used, and (b) the protein's native leader peptide (if present) is used.
A method for the heterologous expression of a protein of the invention, in which (a) the protein's leader peptide is replaced by the leader peptide from a different protein and, optionally, (b) no fusion partner is used.
A method for the heterologous expression of a protein of the invention, in which (a) the protein's leader peptide is deleted and, optionally, (b) no fusion partner is used.
A method for the heterologous expression of a protein of the invention, in which expression of a protein of the invention is carried out at a temperature at which a toxic activity of the protein is not manifested.
A method for the heterologous expression of a protein of the invention, in which protein is mutated to reduce or eliminate toxic activity.
A method for the heterologous expression of a protein of the invention, in which vector pSM214 is used or vector pET-24b is used.
A method for the heterologous expression of a protein of the invention, in which a protein is expressed or purified such that it adopts a particular multimeric form.
A method for the heterologous expression of a protein of the invention, in which the protein is expressed as a lipidated protein.
A method for the heterologous expression of a protein of the invention, in which (a) the protein's C-terminus region is mutated and, optionally, (b) no fusion partner is used.
A method for the heterologous expression of a protein of the invention, in which the protein's leader peptide is mutated.
A method for the heterologous expression of a protein, in which a poly-glycine stretch within the protein is mutated.
The method of any preceding claim, in which the heterologous expression is in an E.coli host.
A protein expressed by the method of any preceding claim.
A heterologous protein comprising the N-terminal amino acid sequence MKKYLFSAA.
Dependencies are inferred from the claim text.